Reprogramming effector protein interactions to correct epigenetic defects in cancer

Number of patents in Portfolio can not be more than 2000

United States of America Patent

PATENT NO 9552457
APP PUB NO 20150154345A1
SERIAL NO

14381588

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

Methods of “reprogramming” epigenetic mark readers or erasers to recognize epigenetic marks other than their cognate (or natural) marks are provided. Reprogramming the reader or eraser can offset the effects of aberrant writer activity (for example, loss of function or overactivity) that can contribute to certain diseases states, such as cancer. The use of the reprogramming compounds identified by these methods in the treatment of such disease states is also provided. Exemplary mark readers that can be targeted by these methods include BPTF and CBX2.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

  • BRITISH COLUMBIA CANCER AGENCY BRANCH

International Classification(s)

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
An, Jianghong Vancouver, CA 3 4
Cheung, Pierre Yulmin Vancouver, CA 1 3
Jones, Steven J M Vancouver, CA 1 3
Thoene, Silvia Vancouver, CA 1 3
Yakovenko, Oleksandr Vancouver, CA 2 3

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
11.5 Year Payment $7400.00 $3700.00 $1850.00 Jul 24, 2028
Fee Large entity fee small entity fee micro entity fee
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00